|
|
|
市場調査レポート
モノクローナル抗体：2009年最新動向
Monoclonal Antibodies: 2009 update
| 発行 |
Datamonitor |
| 出版日 |
2009年11月 |
商品コード |
103027 |
| ページ情報 |
英文 243 pages |
| 価格 |
|
|
当商品の販売は、2012年01月23日を持ちまして終了しました。
Abstract
Introduction
The report provides a comprehensive financial and strategic analysis of the
mAb market, forecasting its commercial evolution out to 2014 and assessing
trends by product, company, therapy area, geography, technology and target
type. It also provides an insight into the direction of mAb technology
evolution and an analysis of pipeline dynamics.
Scope of this research
- Comprehensive financial strategic analysis of the mAb market out to 2014
- Global sales forecasts to 2014 for marketed and Phase III mAb products
- Analysis of market trends by product, company, geography, therapy area,
technology and target type
- Analysis of characteristics of key products and insight into direction of
mAb technology evolution and pipeline dynamics
Research and analysis highlights
The global prescription pharmaceutical market is expected to face a decline in
sales over 2012 to 2013 as a result of the ' patent cliff' . The patent cliff
will impact the small molecule market, in contrast, the mAb market segment
will continue to record robust growth.
Over the forecast period monoclonal antibodies are predicted to enjoy
double-digit growth while small molecule drugs face declining growth rates.
The main barrier to sales growth for small molecules, and particularly in the
US, is exposure to material generic competition, which Datamonitor believes
will have no effect on mAbs out to 2014.
This attractive growth rate and sales return potential has made mAb companies
a prime acquisition target in recent years, even during a period of economic
uncertainty, with a number of key acquisitions made during 2008-09.
Key reasons to purchase this research
- Assess the key products that will drive sales growth in the mAb market to
2014
- Identify the key geographic regions of the global mAb market and the
dynamics within these territories
- Understand the challenges and barriers to entry for new players seeking to
venture into the mAb market
Table of Contents
ABOUT THIS SECTOR REPORT
- PharmaVitae Explorer database
- Chapter structure
- mAb technology overview
- Market analysis
- Pipeline analysis
- Key products
EXECUTIVE SUMMARY
- Key findings
- Monoclonal antibody market outlook
- Introduction to the PharmaVitae company universe
- The prescription pharmaceutical market to 2014
- Prescription pharmaceutical market performance, 2008-14
- Introduction to molecule type analysis
- Prescription pharmaceutical sales by molecule type, 2008-14
- The mAb market will deliver the largest and fastest sales growth across
the industry
- The mAb market is forecast to increase at a double-digit growth rate
- The mAb market will deliver much-needed sales growth in order to offset
US-centered small molecule sales collapse
- Geographic sales growth: the US and 5EU lead the way
- A raft of new mAbs expected to make it onto the market over 2008-14.....
- .....but still only a few mAbs command the highest revenues
- Big 5 dominance will remain, although their share will decline
- Product analysis (size)
- Product analysis (growth)
- Company analysis
- Big Pharma' s hold on the mAb market
- Recent M&A deals underline pharma' s ‘bankable view' of mAbs
- The mAb landscape: innovation driven by collaboration and M&A
- Long-term opportunities and threats
- (Untitled sub-section)
- The price of mAb therapies is a major resistor to growth, but the
collapse of the US branded small molecule market could ‘free-up' payer
resource
- Drive for personalized medicine: the role of companion diagnostics, an
opportunity for diagnostic and mAb players
MAB TECHNOLOGY OVERVIEW
- Key findings
- Introduction
- The immune system
- B lymphocytes and antibodies
- Antibody structure
- Hybridoma technique - the production of mAbs
- Monoclonal antibodies as therapeutic agents
- Targets
- Production of mAbs
- Mode of action
- Evolution of mAbs
- Limitations associated with immunization
- Murine
- Chimeric and humanized antibodies
- Fully human
- Fragments
- Conjugated
- Naked mAbs still dominate
- Systematic naming of mAbs
- The mAb timeline - technology evolution
- Manufacturing
- Mammalian cell culture - still the most widely-used system
MARKET ANALYSIS
- Key findings
- Introduction
- The mAb market - overview of the fastest growing sector across the
pharmaceutical industry
- Key global mAb products over 2002-14
- mAb market product analysis, 2002-14
- Historical product analysis, 2002-08
- Forecast product analysis, 2008-14
- mAb market company analysis, 2002-14
- Historical product analysis, 2002-08
- Forecast company analysis, 2008-14
- mAb market therapy area analysis, 2002-14
- Historical therapy area analysis, 2002-08
- Forecast therapy area analysis, 2008-14
- mAb market geographic analysis, 2002-14
- Historical geographic analysis, 2002-08
- Forecast geographic analysis, 2008-14
- mAb market technology analysis, 2002-14
- Historical technology analysis, 2002-08
- Forecast technology analysis, 2008-14
- mAb market target analysis, 2002-14
- Historical target analysis, 2002-08
- Forecast target analysis, 2008-14
PIPELINE ANALYSIS
- Key findings
- Introduction
- mAb pipeline overview
- Company pipeline analysis
- Late-stage company pipeline analysis
- Early-stage company pipeline analysis
- Change of direction driven by acquisition
- Technology pipeline analysis
- Therapy area pipeline analysis
- Target pipeline analysis
- Target crowding evident with the late-stage mAbs; lifecycle management
strategies being employed
- Novel target early-stage candidates
KEY PRODUCTS
- Key findings
- Introduction
- Oncology
- Avastin
- Herceptin
- MabThera/Rituxan
- Erbitux
- Prolia (oncology)
- Vectibix
- Arzerra
- Immunology & inflammation
- Humira
- Remicade
- Simponi
- Cimzia
- Actemra
- Stelara
- Central nervous system
- Tysabri
- Bapineuzumab
- Campath (CNS)
APPENDIX
- Abbreviations
- Exchange rates
TABLES
- Table: PharmaVitae company coverage by peer set
- Table: Molecule type definitions
- Table: General characteristics of small molecule drugs vs. biologics
- Table: Prescription pharmaceutical sales by molecule type ($m), 2008-14
- Table: The global small molecule market ($m), 2008-14
- Table: The global mAb market ($m), 2008-14
- Table: Annual revenues of the Big 5 ($m), 2008 and 2014
- Table: Overview of a selection of marketed mAbs: technology type and
immunogenicity
- Table: Infix nomenclature for mAbs
- Table: Manufacturing cell lines for marketed mAbs
- Table: Global top five mAb sales ($m), 2002, 2008 and 2014
- Table: Annual revenues of the Big 5 ($m), 2008 and 2014
- Table: Historical mAb product sales ($m), 2002-08
- Table: Forecast mAb product sales ($m), 2008-14
- Table: Historical mAb sales by company ($m), 2002-08
- Table: Forecast mAb sales by company ($m), 2008-14
- Table: Historical mAb sales by therapy area ($m), 2002-08
- Table: Forecast mAb sales by therapy area ($m), 2008-14
- Table: Historical mAb sales by geography ($m), 2002-08
- Table: Forecast mAb sales by geography ($m), 2008-14
- Table: Historical mAb sales by technology ($m), 2002-08
- Table: Forecast mAb sales by technology ($m), 2008-14
- Table: Historical mAb sales by target ($m), 2002-08
- Table: Forecast mAb sales by target ($m), 2008-14
- Table: mAb pipeline overview, 2009
- Table: Count of marketed mAbs by company, 2009
- Table: Count of Phase III mAb players, 2009
- Table: Count of companies with multiple Phase I-II mAb candidates, 2009
- Table: mAb count split by technology type, 2009
- Table: mAb count split by technology type, 2009
- Table: Detailed product/target analysis of mAbs in late-stage development,
2009
- Table: Novel late-stage mAb targets, 2009
- Table: Novel early-stage mAb targets, 2009
- Table: Avastin: overview
- Table: Avastin: sales forecast ($m), 2008-14
- Table: Herceptin: overview
- Table: Herceptin: sales forecast ($m), 2008-14
- Table: MabThera/Rituxan: overview
- Table: MabThera/Rituxan: sales forecast ($m), 2008-14
- Table: Erbitux: overview
- Table: Erbitux: sales forecast ($m), 2008-14
- Table: Prolia (oncology): overview
- Table: Prolia (oncology): sales forecast ($m), 2008-14
- Table: Vectibix: overview
- Table: Vectibix: sales forecast ($m), 2008-14
- Table: Arzerra: overview
- Table: Arzerra: sales forecast ($m), 2008-14
- Table: Humira: overview
- Table: Humira: sales forecast ($m), 2008-14
- Table: Remicade: overview
- Table: Remicade: sales forecast ($m), 2008-14
- Table: Simponi: overview
- Table: Simponi: sales forecast ($m), 2008-14
- Table: Comparison of the route of administration and dosing frequency of
the anti-TNFs in rheumatoid arthritis
- Table: Cimzia: overview
- Table: Cimzia: sales forecast ($m), 2008-14
- Table: Actemra: overview
- Table: Actemra: sales forecast ($m), 2008-14
- Table: Stelara: overview
- Table: Stelara: sales forecast ($m), 2008-14
- Table: Tysabri: overview
- Table: Tysabri: sales forecast ($m), 2008-14
- Table: Bapineuzumab: overview
- Table: Bapineuzumab: sales forecast ($m), 2008-14
- Table: Campath (CNS): overview
- Table: Campath (CNS): sales forecast ($m), 2008-14
- Table: Numax: overview
- Table: Numax: sales forecast ($m), 2008-14
- Table: Synagis: overview
- Table: Synagis: sales forecast ($m), 2008-14
- Table: Xolair: overview
- Table: Xolair: sales forecast ($m), 2008-14
- Table: Prolia: overview
- Table: Prolia: sales forecast ($m), 2008-14
- Table: ReoPro: overview
- Table: ReoPro: sales forecast ($m), 2008-14
- Table: Lucentis: overview
- Table: Lucentis: sales forecast ($m), 2008-14
- Table: Exchange rates, 2009
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: The total pharmaceutical market outlook, sales ($m) and
year-on-year growth rate (%), 2002-14
- Figure: Change in annual sales of PharmaVitae universe by molecule type
($m), 2008-14
- Figure: CAGR of PharmaVitae universe by molecule type, 2008-14
- Figure: Total sales of the mAb market ($m), 2002-14
- Figure: The US versus ex-US small molecule market sales growth ($m and %),
2002-14
- Figure: The US versus ex-US mAb market sales growth ($m and %), 2002-14
- Figure: mAb market geographic analysis, total sales ($m), 2002-14
- Figure: Total number of mAbs versus total mAb market sales ($m), 2002-14
- Figure: Total mAb sales versus average price per mAb ($m), 2002-14
- Figure: Sales proportion of the Big 5 vs. the rest of the mAb market (%),
2002-14
- Figure: mAb product sales ($m), 2002-14
- Figure: Growth driver/resistor products of forecast revenue performance
($m), 2008-14
- Figure: mAb company sales ($m), 2002-14
- Figure: mAb ownership sales by peer set ($m and %), 2002-14
- Figure: Big Pharma' s $74 billion worth of key mAb acquisitions over the
past five years
- Figure: The collaborative landscape of the mAb market key players
- Figure: The structure of an antibody
- Figure: Types of antibodies
- Figure: Immunogenicity ranges
- Figure: Number of marketed mAb technologies, 2008
- Figure: Schematic illustration of antibody fragments
- Figure: mAb timeline - technology shift
- Figure: Total sales of the mAb market ($m and %), 2002-14
- Figure: mAb product sales ($m), 2002-14
- Figure: Growth driver/resistor products of historical revenue performance
($m), 2002-08
- Figure: Growth driver/resistor products of forecast revenue performance
($m), 2008-14
- Figure: mAb sales by company ($m), 2002-14
- Figure: Growth driver/resistor companies of historical revenue performance
($m), 2002-08
- Figure: Growth driver/resistor companies of forecast revenue performance
($m), 2008-14
- Figure: mAb sales by therapy area ($m), 2002-14
- Figure: Growth driver/resistor therapy areas of historical revenue
performance ($m), 2002-08
- Figure: Growth driver/resistor therapy areas of forecast revenue
performance ($m), 2008-14
- Figure: mAb sales by geography ($m), 2002-14
- Figure: Growth driver/resistor geographies of forecast revenue performance
($m), 2008-14
- Figure: mAb sales by technology ($m), 2002-14
- Figure: Growth driver/resistor technologies of forecast revenue
performance ($m), 2008-14
- Figure: mAb sales by target ($m), 2002-14
- Figure: Growth driver/resistor targets of forecast revenue performance
($m), 2008-14
- Figure: Count of marketed mAb players, 2009
- Figure: Count of Phase III pipeline mAb players, 2009
- Figure: Count of companies with multiple Phase I-II mAb candidates, 2009
- Figure: Phase I-III mAb pipeline count split by technology, 2009
- Figure: The stepwise evolution of naked mAb technology
- Figure: Overview of pipeline technology type
- Figure: Phase I-pre-registration mAb count split by therapy area, 2009
- Figure: Count of the most popular targets in early-stage development, 2009
|
 |
